AMLo Biosciences’ Post

AMLo Biosciences were interested in the results of a recent online survey showing that “identifying a true-negative in a low-risk population” would be of particular benefit. The survey, relating to the utility of predictive testing in early-stage melanoma was conducted by Castle Biosciences, Inc. and published in the Journal of Advanced Practitioner Oncology. The #AMBLor technology, available from Avero Diagnostics accurately identifies low risk melanomas. AMBLor can help provide a better prognostic picture at diagnosis, which can assist clinical decision making and also help alleviate patient anxiety at diagnosis. The survey investigated physician assistants and nurse practitioners’ thoughts about the 31-GEP predictive testing for the risk of recurrence in #melanoma. Results showed that over 90% of respondents felt that prognostic information improves treatment planning for melanoma and adds value to patient care. Similar results have been seen in surveys conducted amongst dermatologists and oncologists. https://bit.ly/4ae6nYK #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch

🔬 CD73: A New Prognostic Biomarker in cSCC with Hematologic Malignancy 🧬 Recent research highlights the significance of CD73 as an immunometabolic biomarker linked to poor prognosis in patients with cutaneous squamous cell carcinoma (cSCC) who also have an underlying hematologic malignancy. The study found a significant increase in CD73 levels in patients with worse outcomes, suggesting its potential as a predictive tool and therapeutic target. This could mark a new era in personalized treatment strategies for cSCC patients facing complex conditions. https://lnkd.in/d8AW9kqM #MedicalResearch #Oncology #cSCC #Hematology #Biomarkers #CancerResearch #Dermatology #Immunometabolism

*NEWS* AMLo Biosciences announces this week that our prognostic melanoma biomarker #AMBLor that accurately identifies early-stage melanomas at low risk of progression, successfully received its #UKCA mark and is now available to healthcare professionals.   Dr Marie Labus, CEO, AMLo Biosciences said, “We are excited that AMBLor is available to the NHS and private hospitals. With only around 20% of early stage I or II melanomas progressing to metastatic disease, it is important to identify this group of patients that can be spared further invasive tests and lengthy follow-up schedules. This will free up much-needed healthcare resources and help alleviate NHS waiting lists for skin cancer treatment.” Read the full press release: https://bit.ly/479VHJK #dermatology #dermatopathology #histopathology #histology #oncology #skincancer #cancerresearch #biomarkers #prognostics #healthinvestment #melanoma

It’s day 2 of the Melanoma Focus Patient Conference in Birmingham, UK. The AMLo Biosciences team are delighted to be here listening to the latest updates in #melanoma management from healthcare professionals and patients. Jane Meaney As always, we look forward to hearing the speakers’ thoughts and the concerns and priorities of the patients attending, particularly today’s session on patient research priorities. It is very important to us that we understand the patient perspective to help us develop our prognostic technology that can benefit those with melanoma. #mpc24 #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers #melanomapatientconference

*NEWS*: AMBLor prognostic melanoma biomarker successfully receives UKCA mark and is now available to healthcare professionals.   #AMBLor is a ground-breaking histopathological biomarker test, the first in vitro diagnostic (IVD) of its kind, that can reliably stratify non-ulcerated early-stage I-II melanomas for low risk of progression. With a rising incidence of #melanoma, the deadliest type of skin cancer, and with a 25% rise in NHS England waiting lists for skin cancer treatment, use of the AMBLor prognostic test can segment low-risk patients that could be spared further diagnostic procedures and lengthy follow-up schedules, thereby reducing impact on the UK healthcare system. Read the full press release: https://bit.ly/479VHJK #dermatology #dermatopathology #histopathology #histology #oncology #skincancer #cancerresearch #biomarkers #prognostics #healthinvestment

AMLo Biosciences were delighted to see this recent UK media coverage of our biomarker technology for #melanoma. With funding from the British Skin Foundation, Professor Penny Lovat and her team at Newcastle University were able to develop an innovative assay that identifies the presence of two biomarkers in the skin over a melanoma. The results of this simple test inform doctors whether a melanoma is at low risk of metastasis and therefore, what level of follow up care is needed. https://bit.ly/4bpxJdV The BSF continues to fund further research into biomarkers that help to stratify melanoma metastasis risk and other proteins key relevant to melanoma treatment. amlo-biosciences.com   #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

Microbiome derived biotherapeutics. Microviable Therapeutics SL Microbiome based therapeutics to address unmet challenges in human health. Providing novel solution into infectious diseases, oncology and dermatology. This is the core of our company. We unravel the key features of human commensal bacteria to develop bacterial consortia and complete microbiota ecosystem products generating novel biological drugs and microbiome therapies. We develop this biotherapeutics internally in our state of the art facilities from early stage R&D, with our unique expertise in anaerobic bacteria, to GMP manufacturing to bring our products into clinical trials. More information: https://lnkd.in/dZFjv_83 #microbiome #biotherapeutics #gutmicrobiota #infectiousdiseases #oncology #dermatology #microbiometherapies #biologicaldrugs #bacterialconsortia #LBPs

Hot off the press! Check out our latest case study on Spitz melanocytic neoplasms featuring fascinating MLPH::ALK fusions. We present two cases, including a previously unreported instance of Spitz melanoma, contributing to the expanding knowledge on ALK-fused Spitz melanocytic neoplasms. Please dive in if you love dermatopathology and molecular pathology! #pathology #dermatopathology #molecularpathology #genefusion

AMLo Biosciences were pleased to see that the FDA have approved a novel T-cell immunotherapy, Amtagvi, for advanced #melanoma. Using surgically removed tumour tissue, immune cells are cultured in the lab and then returned to the melanoma patient to attack their cancer cells. https://bit.ly/3ORT47m The new treatment is associated with some challenging side effects, but the new therapy brings hope and a personalised option to patients with limited treatment options. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  #cancerimmunology

Researchers at the Australian National University have developed a new #AI technology to help clinicians identify the most suitable treatment for a range of different cancers. This AI uses #histopathology images from tumours to reduce the current delays in processing complex molecular data needed to identify the best therapy. https://bit.ly/3Wd6JtM At AMLo Biosciences, our team continue working to integrate AI into our prognostic technology #AMBLor, that accurately identifies early-stage melanomas at low risk of progression. The addition of AI will ensure an added second opinion to our already robust testing solution. AMBLor® testing service is provided by @Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as an LDT. www.amlo-biosciences.com #dermatology #dermatopathology #oncology #skincancer #cancerresearch #biomarkers